

Special Issue

Neutralizing-Antibody-Based Treatments for COVID-19: Achievements and Lessons Learnt for Future Pandemics

Message from the Guest Editor

The ongoing COVID-19 pandemic has caused more than 2 million deaths worldwide, which are still counting. Small-chemical antivirals and immunosuppressive treatments are not always efficacious, but passive and active immunotherapies based on neutralizing antibodies show potential. Convalescent COVID-19 plasma is a pioneer in the field, with monoclonal antibodies now entering the market and hyperimmune serum on the horizon. The vaccines approved to date are based on the induction of anti-Spike antibodies. The emergence of Spike variants is affecting the entire field, so challenges will remain for the coming months. In this Special Issue, we will summarize the achievements to date for all treatments based on neutralizing antibodies against COVID-19, and lessons that could prevent errors in future pandemics.

Guest Editor

Dr. Daniele Focosi
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

Deadline for manuscript submissions

closed (28 February 2022)



Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.1
Indexed in PubMed



mdpi.com/si/74331

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

[mdpi.com/journal/
life](https://mdpi.com/journal/life)





Life

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.1
Indexed in PubMed



[mdpi.com/journal/
life](https://mdpi.com/journal/life)



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona
Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)